View Future GrowthStrategic Partners 과거 순이익 실적과거 기준 점검 0/6Strategic Partners은 연평균 78.6%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 64.6%의 비율로 감소했습니다.핵심 정보78.64%순이익 성장률80.43%주당순이익(EPS) 성장률Biotechs 산업 성장률18.72%매출 성장률-64.60%자기자본이익률-4.67%순이익률-277.99%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트공시 • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023모든 업데이트 보기Recent updatesNew Risk • Apr 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.25.4m market cap, or US$3.91m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).공시 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.공시 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (kr.31.7m market cap, or US$4.61m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.32.6m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).공시 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.공시 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.37.5m market cap, or US$5.62m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.33.9m market cap, or US$5.07m).Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.공시 • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.공시 • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.공시 • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Price Target Changed • Sep 01Price target decreased to kr.81.00Down from kr.111, the current price target is an average from 6 analysts. New target price is 146% above last closing price of kr.32.98. Stock is down 63% over the past year.Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (kr.1.5m worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.Major Estimate Revision • Jun 20Consensus revenue estimates fall to kr.95.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from kr.205.5m to kr.95.0m. Forecast losses increased from -kr.7.71 to -kr.9.01 per share. Biotechs industry in Denmark expected to see average net income growth of 0.07% next year. Consensus price target up from kr.111 to kr.127. Share price fell 30% to kr.56.00 over the past week.Price Target Changed • Jun 20Price target increased to kr.127Up from kr.111, the current price target is an average from 3 analysts. New target price is 126% above last closing price of kr.56.00. Stock is down 42% over the past year.Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.분석 기사 • Mar 04What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?If you want to know who really controls Orphazyme A/S ( CPH:ORPHA ), then you'll have to look at the makeup of its...Price Target Changed • Feb 25Price target lowered to kr.135Down from kr.154, the current price target is an average from 6 analysts. The new target price is 82% above the current share price of kr.74.00. As of last close, the stock is down 25% over the past year.Is New 90 Day High Low • Jan 14New 90-day high: kr.78.30The company is up 13% from its price of kr.69.20 on 16 October 2020. The Danish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 12New 90-day low: kr.56.30The company is down 32% from its price of kr.82.50 on 11 September 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.분석 기사 • Nov 19How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?A look at the shareholders of Orphazyme A/S (CPH:ORPHA) can tell us which group is most powerful. Institutions will...Is New 90 Day High Low • Oct 21New 90-day low: kr.66.00The company is down 37% from its price of kr.104 on 22 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 22New 90-day low: kr.80.60The company is down 14% from its price of kr.94.00 on 24 June 2020. The Danish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역Strategic Partners가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CPSE:STRAP 매출, 비용 및 순이익 (DKK Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-13030 Sep 250-23030 Jun 250-33031 Mar 250-23031 Dec 24003030 Sep 240-62030 Jun 240-112031 Mar 240-197031 Dec 230-2613030 Jun 230-2727031 Mar 230-3234031 Dec 220-3841030 Jun 220-4853031 Mar 220-6368031 Dec 210-7883030 Sep 2112-32720413130 Jun 210-43722619431 Mar 210-53523727831 Dec 200-63324736130 Sep 200-52917733630 Jun 200-42510631131 Mar 200-3817829831 Dec 190-3375128530 Sep 190-3124626630 Jun 190-2864624231 Mar 190-2584121831 Dec 180-2303519730 Sep 180-2063917030 Jun 180-1824114531 Mar 180-1543712131 Dec 170-126339830 Sep 170-104238630 Jun 170-82137531 Mar 170-70106531 Dec 160-5885631 Dec 150-53851양질의 수익: STRAP 은(는) 현재 수익성이 없습니다.이익 마진 증가: STRAP는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: STRAP는 수익성이 없지만 지난 5년 동안 연평균 78.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 STRAP의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: STRAP은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: STRAP는 현재 수익성이 없으므로 자본 수익률이 음수(-4.67%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/19 01:55종가2026/06/17 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Strategic Partners A/S는 7명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tazeen AhmadBofA Global ResearchJacob LademannCarnegie Investment Bank ABThomas BowersDanske Bank4명의 분석가 더 보기
공시 • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023
New Risk • Apr 04New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.25.4m market cap, or US$3.91m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
공시 • Nov 25Strategic Partners A/S, Annual General Meeting, Apr 28, 2026Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time.
공시 • Sep 17Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million.
New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (kr.31.7m market cap, or US$4.61m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.32.6m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
공시 • Jan 10Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP).Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired. Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025.
공시 • Dec 27Strategic Partners A/S, Annual General Meeting, Mar 26, 2025Strategic Partners A/S, Annual General Meeting, Mar 26, 2025.
New Risk • Sep 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.37.5m market cap, or US$5.62m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.33.9m market cap, or US$5.07m).
Board Change • Mar 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Feb 22Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024.
공시 • May 31+ 2 more updatesOrphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFOOrphazyme A/S announced that the board of directors and CFO Anders Fink Vadsholt has entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.
공시 • May 18Orphazyme A/S Announces Board ChangesOrphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting.
공시 • Dec 06Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023
Breakeven Date Change • Mar 01Forecast to breakeven in 2024The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Price Target Changed • Sep 01Price target decreased to kr.81.00Down from kr.111, the current price target is an average from 6 analysts. New target price is 146% above last closing price of kr.32.98. Stock is down 63% over the past year.
Executive Departure • Jul 06Independent Director Martijn Kleijwegt has left the companyOn the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Remi P. Droller has left the companyOn the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Executive Departure • Jul 06Independent Director Anders Hedegaard has left the companyOn the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (kr.1.5m worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years.
Major Estimate Revision • Jun 20Consensus revenue estimates fall to kr.95.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from kr.205.5m to kr.95.0m. Forecast losses increased from -kr.7.71 to -kr.9.01 per share. Biotechs industry in Denmark expected to see average net income growth of 0.07% next year. Consensus price target up from kr.111 to kr.127. Share price fell 30% to kr.56.00 over the past week.
Price Target Changed • Jun 20Price target increased to kr.127Up from kr.111, the current price target is an average from 3 analysts. New target price is 126% above last closing price of kr.56.00. Stock is down 42% over the past year.
Executive Departure • Mar 27Independent Director has left the companyOn the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months.
분석 기사 • Mar 04What Type Of Shareholders Make Up Orphazyme A/S' (CPH:ORPHA) Share Registry?If you want to know who really controls Orphazyme A/S ( CPH:ORPHA ), then you'll have to look at the makeup of its...
Price Target Changed • Feb 25Price target lowered to kr.135Down from kr.154, the current price target is an average from 6 analysts. The new target price is 82% above the current share price of kr.74.00. As of last close, the stock is down 25% over the past year.
Is New 90 Day High Low • Jan 14New 90-day high: kr.78.30The company is up 13% from its price of kr.69.20 on 16 October 2020. The Danish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 12New 90-day low: kr.56.30The company is down 32% from its price of kr.82.50 on 11 September 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
분석 기사 • Nov 19How Many Orphazyme A/S (CPH:ORPHA) Shares Do Institutions Own?A look at the shareholders of Orphazyme A/S (CPH:ORPHA) can tell us which group is most powerful. Institutions will...
Is New 90 Day High Low • Oct 21New 90-day low: kr.66.00The company is down 37% from its price of kr.104 on 22 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 22New 90-day low: kr.80.60The company is down 14% from its price of kr.94.00 on 24 June 2020. The Danish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.